Intest Res Search

CLOSE


Intest Res > Epub ahead of print
DOI: https://doi.org/10.5217/ir.2018.00139    [Epub ahead of print]
Published online January 9, 2019.
Clinical aspects and treatments for pediatric inflammatory bowel diseases
Jin Soo Moon 
Department of Pediatrics, Seoul National University Children’s Hospital, Seoul National University College of Medicine, Seoul, Korea
Correspondence:  Jin Soo Moon, Tel: +82-2-2072-3627, Fax: +82-2-743-3455, 
Email: mjschj@snu.ac.kr
Received: 9 October 2018   • Accepted: 11 October 2018
Abstract
The incidence of pediatric inflammatory bowel disease (IBD) is increasing worldwide, especially in the developing countries. It differs from adult disease in clinical manifestations, especially with regard to genetic predisposition in monogenic IBD. Pediatric disease also have a tendency to show more aggressive inflammation and greater extent of lesion. Newer drugs such as antitumor necrosis factor α have been known to make a difference in treating pediatric IBD. Recent studies suggested that the patients with high risk factors might have some benefits from earlier use of biologics. To achieve treatment goals such as relieving symptoms, optimizing growth, and improving quality of life while minimizing drug toxicity, more research is needed to develop tools for risk stratification in the use of biologics for pediatric IBD.
Key Words: Pediatrics, Inflammatory bowel diseases, Crohn disease, Colitis, ulcerative, Anti-TNF-α blockers


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 305, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2019 by Korean Association for the Study of Intestinal Diseases. All rights reserved.

Developed in M2community

Close layer
prev next